Advertisement
Screener

Eton Pharmaceuticals, Inc. (ETON) Graph

ETON Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $37.59M; Cost of revenue $12.18M; Research and development $993.00K; Operating expenses $12.62M.
  • 2026-03-31: Revenue $24.27M; Cost of revenue $9.53M; Research and development $1.88M; Operating expenses $12.32M.
  • 2025-12-31: Revenue $21.28M*; Cost of revenue $8.18M*; Research and development $1.78M*; Operating expenses $10.64M*.
  • 2025-09-30: Revenue $22.46M; Cost of revenue $14.60M; Research and development $1.11M; Operating expenses $9.22M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ETON revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.License$0.00Product$37.59MRevenue$37.59MCost of revenue$12.18MGross profit$25.41MOperating expenses$12.62MOperating income$12.79MResearch & development$993.00KPre-tax income$11.72MIncome tax$140.00KNet income$11.58M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$37.59M$12.18M$993.00K$12.62M$140.00K$11.58M
2026-03-31$24.27M$9.53M$1.88M$12.32M$20.00K$1.55M
2025-12-31$21.28M*$8.18M*$1.78M*$10.64M*-$69.00K*$1.48M*
2025-09-30$22.46M$14.60M$1.11M$9.22M-$28.00K-$1.93M
2025-06-30$18.93M$7.00M$3.71M$13.40M$66.00K-$2.58M
2025-03-31$17.28M$7.42M$1.16M$10.33M$74.00K-$1.57M
2024-09-30$10.32M$4.02M$505.00K$5.79M-$126.00K$627.00K
2024-06-30$9.07M$3.45M$2.97M$8.56M$54.00K-$3.04M
2024-03-31$7.97M$2.96M$651.00K$5.81M$0.00-$811.00K
2023-09-30$7.03M$2.63M$615.00K$4.95M$0.00-$579.00K
2023-06-30$12.00M$2.31M$1.13M$5.80M$0.00$4.56M
2023-03-31$5.30M$1.96M$535.00K$5.88M$0.00-$2.66M
2022-09-30$3.22M$1.20M$744.00K$4.91M$0.00-$3.04M
2022-06-30$7.36M$2.75M$690.00K$5.95M$0.00-$1.56M
2022-03-31$2.18M$849.00K$1.62M$6.41M$0.00-$5.33M
2021-09-30$775.00K$654.00K$2.68M$5.97M(m)-$6.09M
2021-06-30$3.07M$174.00K$1.99M$5.22M(m)-$2.02M
2021-03-31$11.90M$1.59M$886.00K$4.94M(m)$5.12M
2020-09-30-$161.00K$144.00K$2.83M$6.25M(m)-$6.50M
2020-06-30$20.00K$28.00K$1.61M$4.53M(m)-$4.73M
2020-03-31$99.00K$102.00K$6.27M$8.88M(m)-$9.05M
2019-12-31$459.00K(m)(m)$2.66M(m)-$2.70M
2019-09-30(m)(m)$3.42M$5.04M(m)-$4.96M
2019-06-30(m)(m)$1.44M$3.35M(m)-$3.25M
2019-03-31$500.00K(m)$6.46M$8.05M(m)-$7.41M
2018-12-31(m)(m)(m)$2.29M(m)-$3.73M
2018-09-30(m)(m)$1.54M$2.37M(m)-$2.91M
2018-06-30(m)(m)$1.71M$2.70M(m)-$3.08M
2018-03-31(m)(m)$1.27M$2.96M(m)-$3.02M
2017-09-30(m)(m)$1.56M$2.77M(m)-$2.80M

Revenue and expense 5 month

Period endResearch and developmentOperating expensesNet income
2017-09-30$3.07M$4.95M-$4.99M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$61.85M$21.71M$2.87M$24.94M$160.00K$13.13M
2025-06-30$36.21M$14.43M$4.87M$23.73M$140.00K-$4.16M
2024-06-30$17.04M$6.41M$3.62M$14.37M$54.00K-$3.85M
2023-06-30$17.30M$4.27M$1.66M$11.68M$0.00$1.90M
2022-06-30$9.53M$3.59M$2.31M$12.37M$0.00-$6.89M
2021-06-30$14.96M$1.80M$2.88M$10.13M(m)$3.10M
2020-06-30$119.00K$130.00K$7.88M$13.41M(m)-$13.78M
2019-06-30$500.00K(m)$7.90M$11.40M(m)-$10.66M
2018-06-30(m)(m)$2.98M$5.66M(m)-$6.10M

Revenue and expense 8 month

Period endResearch and developmentOperating expensesNet income
2017-12-31$3.93M$7.15M-$7.16M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$58.67M$29.03M$5.99M$32.95M$112.00K-$6.08M
2024-09-30$27.36M$10.43M$4.13M$20.16M-$72.00K-$3.23M
2023-09-30$24.33M$6.90M$2.27M$16.63M$0.00$1.32M
2022-09-30$12.75M$4.79M$3.05M$17.28M$0.00-$9.93M
2021-09-30$15.74M$2.46M$5.55M$16.09M(m)-$2.99M
2020-09-30-$42.00K$14.00K$10.70M$19.66M(m)-$20.28M
2019-09-30$500.00K(m)$11.32M$16.45M(m)-$15.62M
2018-09-30(m)(m)$4.53M$8.04M(m)-$9.01M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$79.95M$37.21M$7.76M$43.58M$43.00K-$4.60M
2024-12-31$39.01M$15.60M$3.25M$26.01M$15.00K-$3.82M
2023-12-31$31.64M$10.58M$3.32M$22.25M$247.00K-$936.00K
2022-12-31$21.25M$6.93M$4.00M$22.58M$0.00-$9.02M
2021-12-31$21.83M$2.83M$6.24M$20.50M$0.00-$1.96M
2020-12-31$39.00K$436.00K$14.10M$26.71M(m)-$27.97M
2019-12-31$959.00K$453.00K$11.55M$19.11M(m)-$18.32M
2018-12-31(m)(m)$5.63M$10.32M(m)-$12.74M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xencor Inc (XNCR)United States$1.776B-7.33
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Septerna, Inc. (SEPN)United States$1.783B-63.01
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
COMPASS Pathways plc (CMPS)$1.812B-4.87
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20